Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary

February 23, 2022

New York Stock Exchange US Information Technology Electronic Equipment, Instruments and Components earnings

Earnings Call Speaker Segments

Company Representatives

executive
#1

On the call we have Larry Kingsley, our Chairman; Tom Logan, our Founding and Chief Executive Officer; Brian Schopfer, our Chief Financial Officer; and Alex Gaddy, our Vice President of Finance and Investor Relations.

Alex Gaddy

executive
#2

Hello, everybody, and thanks for being here on Mirion's earnings call, where we're reporting financial results for Q4 and the entire year that closed on December 31, 2021. I'm Alex Gaddy, VP of Finance and Investor Relations at Mirion, and I'll be your moderator for today's event. Just a few administrative notes before we begin. Please keep in mind that what we discuss in this presentation will contain forward-looking statements, and actual outcomes could vary materially from what those forward-looking statements project. The elements that might lead actual outcomes to vary are covered in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which we submit periodically to the SEC, under the heading Risk Factors, as well as in other filings Mirion makes with the SEC. One reminder: any quarterly references made during today's discussion pertain to the fourth quarter that ended December 31, 2021, unless we say otherwise. What we cover during this call will also feature certain financial measures not prepared in accordance with Generally Accepted Accounting Principles. You can locate a reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix of this presentation for this conference call. Be aware that a Q&A session will come after today's prepared remarks. Today, our earnings presentation and transcript will be released and are available on Mirion's IR website at ir.mirion.com. With me on the call today are Larry Kingsley, Chairman of the Board; Tom Logan, Founding, Chief Executive Officer; and Brian Schopfer, Chief Financial Officer. At this point, I'll hand things over to our Chairman of the Board, Larry Kingsley. Larry.

Larry Kingsley

executive
#3

Thanks, Alex, and good morning to all of you. We’re grateful for your interest in Mirion, and it’s a pleasure to report our results for the fourth quarter and the full year 2021, along with our outlook for the business in fiscal year 2022. Before handing things over to Tom, I want to spend a few minutes walking through some of the main points from ‘21 and offer my perspective on where the company stands as we enter ‘22. Mirion keeps evolving and progressing on its path as a public company, and there’s plenty to feel optimistic about ahead. Every one of the themes I discussed on our November call is still in place, and I want to stress again how well positioned Mirion is to take advantage of what we see as a favorable macro backdrop spanning the company’s diversified product portfolio. There are three main points I’d like you to take away from my remarks this morning. First, despite facing numerous obstacles in the fourth quarter, the company still posted solid results. From the Omicron variant’s surge, to the condition of the global supply chain, to headwinds in labor supply, to the company wide push required to complete the transition to being public, Mirion managed to grow its business and move forward on many of its key strategic initiatives. Second, the company specific and macro growth opportunities across the product portfolio are demonstrating that they can be sustained. That takes in favorable trends in both the industrial and medical segments, plus a healthy M&A pipeline, as shown by the recent CIRS acquisition. Third, and perhaps most significantly, the team at Mirion brings a strong track record and is adjusting well to the needs and requirements that come with being a public company, just as all of us anticipated. Tom Logan has an excellent reputation for generating meaningful returns for investors across close to two decades, and my confidence in his ability to lead the talented team at Mirion toward what I see as a promising future for the company is stronger than ever. Having successfully taken Mirion public, Tom can now refocus on what he does best, running his business and executing on meaningful growth opportunities. I want to emphasize once more just how unique Mirion’s story is; this is a solid company with resilient underlying markets and a diverse and differentiated product portfolio with high barriers to entry. Mirion holds leading positions within its chosen markets, and I’m eager to see what the company can achieve as it continues to deliver on its strategic priorities going forward; working alongside Tom, I believe there is a strong opportunity for operating margin expansion as Mirion develops and enhances its ability to gain on pricing and cost efficiencies. Consistent execution of the Mirion operating system will generate returns, and Mirion’s strength in that area is especially notable. We are pleased with how Mirion is performing as a new public company, particularly given the environment and operational challenges that all companies are facing at the moment. Having said that, I'll now hand things to Tom, and he'll take us through the market as well as how the business performed, covering that in some detail.

Tom Logan

executive
#4

Thanks, Larry. Before I get started, I want to add my own agreement to what Larry said regarding how strong and relevant our partnership is; having someone in my corner who can serve as both an ally and a strategic sounding board—bringing the industry knowledge, the relationship capital, and the standing that Larry does—means a great deal to me. I also want to express my gratitude to all 2,600 of my coworkers around the world who have gone the extra mile to help us complete our transition to being a publicly traded company, to propel our strategy forward, and to steer us through an extraordinarily difficult operating climate. What all of you do matters enormously when it comes to protecting human health and the health of our planet. I'm delighted that we managed to make our public market debut successfully, though honestly, I have to admit I'm eager to return to leading the business on a full-time basis. There's plenty ahead of us, and we're in a very strong position to deliver in 2022. Now, starting on slide four of the deck, I want to spend a few minutes walking through how we see the different markets we compete in and to share our forecast for the year ahead. I'll start with the medical segment, which represented 34% of our total company revenue in 2021. We anticipate delivering high single digit growth in 2022, and we're keeping a favorable view across Dosimetry, Nuclear Medicine, and Radiation Therapy QA. I want to restate our objective for medical to surpass more than half of our total company revenue over the longer term planning horizon; in occupational Dosimetry, we compete in a steady market and rely on a subscription based business model, with substantial amounts of recurring revenue. Our outlook on this space remains positive, and we expect growth to come from moving existing customers onto our innovative digital Instadose platform as well as picking up market share internationally. In Nuclear Medicine, we take encouragement from numerous factors bolstering this space, among them favorable demographic trends, an improving supply chain for medical isotopes, and the exciting expansion of Theranostics applications. Although we've run into some acute near term supply chain difficulties in this space, demand for our products is still extremely robust, and I'm confident that order fulfillment will be back on track by the end of the first half. Lastly, the radiation therapy business keeps benefiting from strong demand fundamentals driven by clinician preference for independent quality assurance solutions, along with improving post pandemic demand dynamics. We feel good about our new product pipeline as we head into calendar year '22, and we're especially enthusiastic about the incipient launch of the first cloud based version of SunCHECK, our industry leading QA workflow software platform. Moving on to the industrial segment, we continue to expect mid-single growth in 20 — mid-single digit growth in 2022; we're greatly encouraged by the positive sentiment in the nuclear power end markets, particularly when it comes to the role nuclear plays in supporting the global decarbonisation movement. We anticipate favorable momentum coming from lifetime extensions, replacement demand driven by demographics, robust government incentives, and elevated natural gas prices. On the new build side, we see activity continuing to rise as the reduction of carbon emissions stays front and center within the worldwide environmental movement. I'm pleased as well to share that during the fourth quarter we secured significant new build awards in China and Brazil, which further strengthen our medium and longer term outlook; honestly, across almost 20 years serving as CEO, conditions in the nuclear sector have never looked stronger to me. The installed base remains in good shape, new build work keeps picking up speed, and decommissioning prospects are firm. Moving beyond the lab and research segment, a comparatively vigorous market has benefited us, helped by tougher environmental rules and dependable government funding. Going forward we anticipate ongoing steadiness along with steady expansion, underpinned by our fresh product pipeline. Now let's move to our December results, which appear on slide five of the earnings presentation. I want to start by pointing out that our acquisition of CIRS closed in December, and we look forward to completely folding that company into our operating model while capturing the advantages we recognized during diligence; during the quarter, organic revenue growth came in at 2.7% versus the matching calendar stretch in 2020. For the entire year, organic revenue growth reached 3.6%. As noted before, supply chain pressures, chiefly the availability of components, have held back our Nuclear Medicine business, dragging down growth both in the quarter and across the year. We have been striving to bring additional suppliers on board and striking inventive arrangements to make up for these shortfalls. I feel good that this tough stretch is almost behind us. Order intake during the quarter was solid, encompassing the sizable orders referenced earlier. Year-end backlog stood at close to $750 million and keeps reinforcing our medium to longer term outlook. Our sales teams, who have labored tremendously hard everywhere in the world, make me extremely proud, and the strength of our backlog offers the plainest proof of what they have achieved. Alongside the difficult supply chain conditions, we have taken forceful pricing steps to push back against the mounting inflationary pressures that have filled recent headlines. Because so much of our backlog eventually reaches the P&L, it matters to recognize that a built-in delay exists before pricing moves show up in our financial results. Actions already taken are projected to generate no less than 200 basis points of pricing growth, weighted toward the latter portion of 2022, exceeding what inflation is expected to cost us. Before handing things to Brian for a closer look at our financial performance, I'd like to briefly walk through what we expect for 2022. As a reminder, we have shifted our fiscal year from a June 30 to a December 31 year-end, and guidance will reflect the 12 months ended December 31, 2022. When it comes to reported adjusted revenue growth, we're looking for something in the 5.5% to 7.5% range, while organic growth should land between 5% and 7%. On adjusted EBITDA margins, our target sits at 24% to 25%, and that figure assumes 100 to 200 basis points of expansion once you strip out the impact of public company G&A costs. As we work through our 2022 operating plan, there are three main areas where our team will concentrate. The first is commercial and pricing excellence. Beyond the actions we've already taken, we're rolling out an improved set of value based pricing tools. The second area is our ongoing investment along with strategic cost savings initiatives. The most notable step here is the streamlined operating model we've put in place, which we believe will cut down on complexity as time goes on, and on top of that, the company keeps optimizing its industrial footprint while integrating newly acquired assets. And finally, combining the new pricing tools with operating initiatives that are already in motion ought to deliver strong operating leverage this year. There's plenty ahead for us across the whole enterprise; the trends showing up in our order books and in the underlying markets give us a lot of encouragement. With all that said, let me hand things over to our Chief Financial Officer, Brian Schopfer, who will walk through our financial performance and 2022 outlook in greater detail. Brian.

Brian Schopfer

executive
#5

Thanks, Tom. To begin, I want to express gratitude to our team for the effort and commitment they showed in helping us wrap up our initial year-end since becoming a public company. I also want to thank the investors and analysts who joined the call for spending their time learning about our business. We're grateful for the time you've given us and we're eager to keep building on the relationship we've built so far. So with that, let's move to slide seven and examine our fourth-quarter results more closely. As Tom mentioned, our team turned in a strong performance, with total revenue rising 20% and adjusted EBITDA rising 17%, both measured against the equivalent calendar period a year earlier. Organic revenue for the whole company climbed 2.7%, mainly because of how our industrial business performed, partially offset by the Nuclear Medicine difficulties Tom brought up. Sales for the quarter totaled $180.9 million, accompanied by adjusted EBITDA of $44.8 million. For the quarter, adjusted gross margin widened 300 basis points to 51%, while adjusted EBITDA margin slipped modestly, falling 70 basis points to 24.7%. The increase in adjusted gross margin came from our medical segment accounting for a larger share of Mirion's total company revenue. That gain gets offset further down the P&L by elevated operating expenses tied to recent acquisitions in the medical segment, ongoing growth-oriented R&D investment and corporate costs stemming from public company requirements. Turning to how we did across the calendar year, we posted adjusted revenue growth of 32%, along with 3.6% organic revenue growth and adjusted-EBITDA growth of 29% year-over-year in 2021. Our adjusted gross margin rose 280 basis points to 51%, yet adjusted EBITDA margin fell 60 basis points to 24.2% versus the prior year. Operating expenses connected to going public and the Biodex acquisition diluted margins, which weighed on adjusted EBITDA margin. Now let's shift to slides eight and nine to review our quarterly and calendar year results by segment, beginning on slide eight with the medical segment. Adjusted revenue climbed 91% while organic revenue stayed roughly flat. Keep in mind that organic growth gets only a limited contribution from the Sun Nuclear acquisition completed in December of 2020. Supply chain problems we encountered within our Nuclear Medicine business were the main factor affecting our organic growth in this segment. The adjusted EBITDA margin for the Medical Segment came in at 32.4%, down 80 basis points from the equivalent period a year ago, largely because of the anticipated dilutive effect of recent medical acquisitions. We remain focused on integrating these acquisitions and anticipate our margin profile will strengthen as those efforts progress over the coming quarters. Moving to slide nine, the industrial segment posted adjusted revenue growth of 1.1%, with organic revenue up 3.3% from the equivalent period a year earlier. Industrial adjusted EBITDA rose 1.4% versus the equivalent period a year earlier. Adjusted EBITDA margin held steady because of mix, strengthening U.S. The effects of the dollar and inflation are also worth noting. In addition, I want to point out a few important items when we look at our capital structure and where liquidity stands right now. On slide 10 in the earnings deck, you can see we held $84 million in cash-on-hand along with $166 million of available equity, and that figure includes the $82 million undrawn revolver. From our CIRS acquisition, there was a net cash use during the quarter that came to $54 million, and right after closing it raised our net leverage on a nominal basis. For the six month period ending December 31, 2021, adjusted free cash flow came in positive relative to the prior year. The improvement was driven by higher adjusted EBITDA as well as solid performance in net working capital. Now, moving to slide 11, I'll walk through additional specifics regarding our full year 2022 guidance. As Tom mentioned before, the reported adjusted revenue guidance we've issued is 5.5% to 7.5%. Organic growth should land somewhere between 5% and 7%. For the year, FX is anticipated to hurt reported revenues by roughly 1.5%, and finally, CIRS is expected to contribute 2% in organic growth. For calendar year 2022, the adjusted EBITDA target range is $175 million to $185 million, while adjusted EBITDA margin should fall between 24% and 25%. We are aiming for 100 to 200 basis points of adjusted EBITDA margin expansion, not counting the impacts of public company G&A costs; we anticipate roughly $11.5 million in incremental public company G&A cost this year, which will bring about an estimated 150 basis points adjusted EBITDA margin reduction. The adjusted EPS outlook for the year should come in between $0.45 and $0.50 per share, and adjusted free cash flow is projected to be positive $90 million to $110 million. To assist with modeling considerations, we are using our outstanding share count as of December 31, 2021 to set guidance, we expect our effective tax rate to be 24% to 26%, and we are assuming a U.S. dollar to Euro FX conversion rate of $1.13. With that said, let me hand things back to Tom to wrap us up.

Tom Logan

executive
#6

Thanks, Brian. Ahead of taking your questions, I'd like to share a handful of final remarks. To start, Mirion experienced an enormous year in 2021, the year we transitioned into a publicly traded company. That required an enormous effort and an enormous internal commitment of resources, and the outcome has left us extremely pleased — though honestly, I'm also eagerly anticipating getting back to concentrating on operations as we move through 2022. Next, the markets we serve are in good shape; and last, our confidence in the strategy is strong. So to wrap up, I want once more to express my heartfelt gratitude to my teammates across Mirion, and now I'll hand it back to you, Alex.

Alex Gaddy

executive
#7

Thanks, Tom. That wraps up the remarks we had ready for today. At this point, we're going to begin the Q&A session. So with that, I'll hand it back to the operator so we can get started.

Joe Ritchie

executive
#8

Hello there! Morning to Larry, Tom, Brian, and Alex. It's wonderful to be here with all of you today, and I'm grateful for all the information shared earlier.

Tom Logan

executive
#9

Thank you, Joe.

Brian Schopfer

executive
#10

Thank you, Joe.

Joe Ritchie

executive
#11

Alright, before I begin, Ronny Scardino is also part of my team, and I believe we'll alternate on some of these questions; so perhaps I'll start things off and then hand it over to Ronny; we'll simply go back and forth. But the first thing I want to ask is really, look, you've completed two quarters as a publicly traded company. We understand that this also sort of lines up with what is likely the most difficult supply chain environment that nearly all of us have encountered; however, the question really concerns organic growth and the level of confidence you possess in hitting that 5% to 7% long-term objective, and what has been assumed in your 2022 guidance, considering that we haven't actually observed it during the initial couple of quarters, so maybe let's begin there.

Tom Logan

executive
#12

Yes, Joe — Tom here. What I'd say is that our confidence hasn't wavered at all regarding that 5% to 7% of gross figure we provided guidance on during the entire process of becoming a public company, and that covers the pipe raise along with the official de-stacking. Why do we feel that way? Because, once more, consider the market conditions we discussed earlier today within each reporting segment. Take the industrial segment first, where commercial nuclear power is the primary driver. Honestly, I can't emphasize enough how strong the underlying dynamics are in nuclear right now. During my prepared comments I mentioned that I've now been with the company for over 18 years, and when we examine the core elements of nuclear power — which for us means installed base dynamics, new build activity, and decommissioning activity — tremendous strength shows up in all three, backed by the ongoing push to decarbonize the world economy, shifting dynamics in alternative energy supply, and most notably the big year-over-year jump in natural gas pricing, plus the enormous new build activity that's largely fueled by regional energy security requirements. Taken together, these factors make nuclear very appealing to us, and as I mentioned, that's reflected in our order intake and in our backlog. Then, looking at industrial's other sectors — life-sciences or lab space, military and defense, and other industrial applications — for the same reasons I just cited, strength is evident there too, both in the current year and, looking forward, we anticipate that strength will persist. Last, regarding the medical segment, the dynamics match what we guided before. On radiotherapy, demand is strong, driven not just by radiotherapy clinics expanding worldwide, but also by the new product pipeline we've concentrated on heavily, which I expect will keep producing exciting results down the road. We touched on the Nuclear Medicine space and voiced a degree of disappointment about supply chain constraints during the current quarter and across the six month reporting period, and to be clear, demand in this space is extremely strong. Our backlog sits at record levels; we've simply been limited in shipping product because of a few very narrow, very specific subcomponent availability issues, and as I said, we're working diligently to resolve that. When we look further out, we stay quite optimistic about this area. And then last, in occupational Dosimetry, as we mentioned, we have a lot of confidence in the technology platform we built, which we call Instadose, and in how that digital platform can be leveraged around the world. So each of those elements adds up to solid growth in the underlying market. On top of that, consider what we're doing as a business: as we build scale and sophistication, getting better at covering the market and narrowing in on specific areas, we're even seeing that we're typically the other number one participant across most of our product categories. In certain cases our share position is somewhat uneven, and we're putting in a lot of effort to shut those gaps overall. Together, those elements, plus a sharper emphasis on pricing juristics and a really robust pipeline of new products, should, in our opinion, sustain the growth range we've provided guidance on the whole way through.

Brian Schopfer

executive
#13

Joe, Brian here, just a couple of smaller points to add. First, I'd really stress that within our organic growth figures, there's only a small contribution from Sun, and as we've discussed previously, Sun is certainly expanding at a high single-digit rate, so I'd factor that in as well. Second, I should note that our first quarter is going to be the most difficult comparison we'll face over the course of the year. The quarter we just completed, as you know, was measured against — that's a double-digit comparison, so that one will be the hardest comp when we look at it, and I believe we've included all of that in the materials we released this morning.

Joe Ritchie

executive
#14

Right, that's excellent. Tom, thank you for that response, and Brian, it was really nice to see all the segment-level information you provided each quarter in the presentation. Tom, I'd like to build on something you mentioned during your prepared remarks regarding nuclear, since that's a topic we receive many inquiries about. You stated that at no other moment in your entire time in this field have you witnessed a better juncture than what the nuclear sector presents right now, and I'm simply wondering — you're looking at your guidance of low single digit growth for 2022. I'm attempting to reconcile those two things — that remark alongside the growth projections — and whether you might offer some additional insight past 2022 concerning the various portions of your operation, be it decommissioning, new builds, or the installed business.

Tom Logan

executive
#15

Okay, Joe, here's how I'd frame the whole thing. First off, let me point out that when you add up everything we do tied to nuclear power, that accounts for roughly 38% to 39% of total revenue, and that piece can be broken into the three subcategories I mentioned earlier. The installed base usually makes up around three quarters of the revenue linked to nuclear power. Activity around new build or new construction generally falls somewhere in the 15% to 20% band, while decommissioning work, which is genuinely still in its early stages. The developing market as a whole accounts for what's left, so it starts with the installed base. If you go back across the last couple of decades and examine some of what's happened inside the installed base of nuclear power, you'd notice plenty of difficulties — for instance, in the U.S. you've had a circumstance where the companies running nuclear plants, and roughly 93 of them are operating in the United States today, with around half of those having sold their power into deregulated markets. And when you consider market conditions across the past decade, during which we've witnessed a major proliferation of combined cycle gas, turbine power plants, you've observed some unusual demand patterns as we emerge from the great recession overall; you've seen the increased impact of heavily subsidized wind and solar power and all of those factors created stress for the American nuclear base, which at its peak created a situation where about 30% of the American fleet was economically challenged and potentially facing shut down situations. Jumping ahead to now, if you were to examine that installed base and truly treat it as a proxy, conditions differ by region in other parts of the world, but let's use this as a proxy for how the dynamics have shifted. That is, when you look at the present moment, what you've witnessed is that first, substantial subsidies have been provided to the people operating nuclear power stations, at the state level as well as from the federal government, and within the most recent infrastructure legislation there's roughly $6 billion of operational subsidies for nuclear power plants, all of which is obviously meant to keep them open, to keep them profitable, to keep them spending capital overall. Beyond that, if you consider more or less the macro market conditions, once again as I said earlier, the real key driver behind the relative economics of combined cycle gas turbine power plants versus nuclear power is what gas costs, and as people have observed, those overall natural gas pricing has more than doubled on a year-over-year basis and the general outlook there you know is that it will remain high for an extended period of time. What all of this adds up to within the installed base is that operators now have greater confidence in whether nuclear power plants make economic sense, and because of that, a number of things happened. To start with, they usually operate at elevated capacity factors—that's the industry's technical phrase for how much a plant is utilized. Next, they're allocating greater amounts of capital, and we'll observe that happening during the peak outage periods in spring and fall, when the bulk of maintenance and upgrade spending across power plants takes place, and quite often folks are once again discussing additional life extension for the units already in place. Again, you know, it's a complicated response, yet if I use the United States as an illustration of how market conditions have shifted, what all of this ultimately amounts to is that operators now feel far more assured about the economic viability of their plants, the timeframe over which they'll run them, and all of that once more generally pushes capital expenditures higher. Turning quickly to new build activity, I'm certain lots of people have noticed the considerable activity taking place beyond the United States. We don't anticipate meaningful new build activity in the U.S., yet at this moment, were you to examine this segment as a whole along with our growth expectations, we believe it will be among the quickest expanding parts of our business as a whole, and that's based on activity happening across Europe and in the Pacific Rim in the NIM <<inaudible>> and crucially it's backed by backlog. So if you were to review our internal expectations regarding growth in new build activity, which once more are fairly optimistic, you'd discover that the overwhelming majority of that—and by overwhelming majority, I mean considerably more than three quarters—is backed by backlog we currently hold, and if you were to include in that backlog number the bidding activity, the quotation activity where we're answering RFPs and RFQ’s, that coverage figure reaches 90% or better; now, all of which means this isn't something we anticipate occurring; it's something already occurring. You know, it essentially encompasses once more a highly optimistic internal projection for new build activity that extends across our planning horizon. The last point I'd make is that when you consider decommissioning, which once more is a market still developing, and that's truly propelled by the reality that among the approximately 450 nuclear reactors operating worldwide, a great number of them were constructed during the 70’s and 80’s, and there's a highly predictable decommissioning trajectory that will unfold over time, and we're starting to witness it. You know, we've moved past the leading edge, entering a quickening pace of decommissioning activity as a whole, which is a net positive for the company, since we take part extensively in that decommissioning work; so, you know, I think you grasp the idea. I could continue for a good while on this topic, but the takeaway is once more that the overall demand dynamics look favorable. The figures we're seeing in the market give us a lot of confidence, and let me be clear: we're putting in serious effort to keep advancing and expanding what we bring to the industry, so that productivity improves and so that what today is an almost completely analog sensor base gets digitized, and looking forward, we believe there will be even greater opportunities to take advantage of those elements.

Joe Ritchie

executive
#16

Sure, that tracks. I believe Ronny has a brief question — something further to ask Brian.

Ronny Scardino

analyst
#17

Yeah, thanks guys. This is Ronny Scardino, and I'll just — I'll jump in next; so Brian, you mentioned that 1Q is the hardest comparison. So I just want to try to get a handle on how uneven growth really is in this business, and whether there's any seasonality to it. Basically, I'm just trying to figure out how far growth in any single quarter should stray from that long-term growth framework, and in particular, do you think 1Q growth would be negative?

Brian Schopfer

executive
#18

Yeah, so as I said, I believe the first quarter is our hardest comp, right, double digits. My sense of where we are right now is that this period will be pretty much level, more so than anything else. Looking at what's left of the year, the remainder of this quarter, I'd anticipate, you know, solid expansion across all three quarters. Our comparison for Q2 and Q3 is considerably softer, which we've now made public, and I'd say things look reasonably even once the first quarter is behind us. One more point worth noting: since we've moved from a fiscal year to a calendar year, I believe we're currently experiencing — and likely will continue to experience — some revenue shifting out of what used to be our June quarter and into the September quarter. Honestly, I view this as a good development for the company, and everything will even out, along with our planned workload and so on; so I do anticipate some of that movement. If we're looking at how the year typically breaks down, the rough guideline we use is this: quarter one brings in about 20%, quarter two around 30%, quarter three about 20%, and quarter four roughly 30%. That's more or less the split we anticipate when it comes to the revenue percentages.

Ronny Scardino

analyst
#19

Understood. That's useful. Maybe if we pivot quickly to incrementals — the guidance implies mid-20s, you know, on an incremental basis, if you exclude <<inaudible>>, which looks conservative given the long-term objective, which I believe roughly doubles that on an incremental basis. So my first question is: how do you feel now about that long-term incremental target, and then what's driving margin in particular in 2022?

Brian Schopfer

executive
#20

Let me step back and address '22 briefly. Essentially, it's mostly about absorbing our public company costs. What we discovered, going through this process and building it into our planning cycle, is that being public costs somewhat more than we anticipated, and certain items aren't within our control. These aren't nice-to-have items. It's insurance, and so on. So when you look at the incrementals from '21 to '22, it's largely a public company costs matter, plus a bit of mix, right. So there's some mix involved — slightly more new build, slightly less recurring. We always saw that coming. It's perhaps somewhat heavier than we initially planned, but I think we're fine with it. Looking ahead, I believe this is the biggest year for us to absorb cost, and I expect our longer-term guide of reaching 30% margins is something Tom, Larry and I are intensely focused on.

Ronny Scardino

analyst
#21

Yes, that helps. And could you remind us — I recall there was some talk at one stage about pushing more corporate costs down into the segment. Did that happen with this extra data you've provided, or should we look for it over the coming quarters?

Brian Schopfer

executive
#22

Sure. My guess is we'll surface again at some point during the first half of the year with additional detail on that. In our planning, a couple of million dollars did shift out of corporate and into the industrial segment; that move didn't take place in Q4. So there was a bit of noise there that will show up in the '22 figures, though any wider reallocation will also resurface around that same point in the first half. I'd like to keep things tidy and then as cool as we can.

Ronny Scardino

analyst
#23

Thank you, Brian. All right, I'll hand things back over to Joe1.

Joe Ritchie

executive
#24

Right, we'd certainly be overlooking something if we failed to raise the topic of M&A with you all. It's obviously front and center in investors' minds, since it serves as a way to fuel growth on the top line as well as widen margins. So I suppose my opening question would be this: looking at the short term, does M&A remain the priority, or has paying down balance sheet debt become the bigger emphasis right now?

Tom Logan

analyst
#25

Tom here. Both of those things matter, I'd say. First, on the M&A front — when you examine the record we've built, finding good deals that fit strategically, getting them signed at appealing multiples before synergies, and then bringing them together successfully, we've performed well across each of those dimensions. It has contributed enormously to how the whole business has grown, not just across the past 5 years but through our longer history as well. That's going to keep being true, and the guidance we've provided — 5% to 10% from inorganic growth — remains, I believe, very sustainable. A couple of points worth flagging: first, when you factor in what CIRS brings, roughly 2% of extra growth gets added to the CY ‘22 topline. And looking further out, regarding our capacity to keep adding more deal flow that moves us into that range, our confidence holds. Turning to leverage, plainly our position and what we expect is that across the intermediate to longer term — definitely within our planning horizon — we will quite intentionally work to delever this company. The goal we've historically referenced, and which we still hold, is getting leverage down to somewhere in the 3x to 3.5x range in total, meaning leverage expressed as a multiple of the company’s overall EBITDA. As of today we're slightly above — roughly 4.3x — and we recognize investors want and expect that figure to come down going forward. Still, considering the free cash flow the business produces — around $100 million in total — and applying a sensible set of assumptions about entry multiples, EBITDA margins, synergies available right away, and so forth, I'd say we stay comfortable that inorganic growth can again be added within the range we've guided, alongside modest deleveraging in the near term, so our view definitely holds. Let me wrap up my remarks by saying that our pipeline at present is excellent. We stay quite busy building a pipeline aligned with the business's strategic objectives, and about where we stand on that front right now, we feel very good.

Joe Ritchie

executive
#26

That's really useful. And let me just clarify something you said a moment ago, Tom — regarding that link to cash flow, is the idea that cash will fund the deals and you can still deliver through cash, or are you likewise thinking about doing deals with equity.

Tom Logan

executive
#27

Well, I’d say to you that right now we aren’t planning to tap equity for funding transactions, though what we believe is that by pairing cash with what would be a proportionally smaller amount of added leverage, in the end a route exists, a path is available for us to once again run things inside the boundaries we’ve set, achieving nominal deleveraging across the whole business.

Joe Ritchie

executive
#28

Understood, all right. Then a handful of additional quick points of clarification. I'm also mindful of how much time you have, so I'm grateful for every question raised on today's call, but there are a few things investors have asked us about too. Regarding the first, I believe earlier you mentioned something about pricing exceeding inflation, 2 points in the back half of the year. I suppose just to make that clear, the idea is, does that mean 2 points above inflation, or is it 2 points not counting inflation. Just attempting to grasp what framework you have in mind for 2022.

Brian Schopfer

executive
#29

That works out to just 2 points from price alone. When it comes to net inflation, that figure is actually smaller. Another way to look at it, thinking about how things sequence, is that price costs are going to be negative during the first quarter, then flat in the second quarter, and clearly after that we pick up some ground over the back half of the year. And I wouldn't say — what I'd share is that we aren't assuming a massive margin lift from prices versus costs; there is a bit of one, but it isn't a large figure.

Joe Ritchie

executive
#30

Alright, yes, that's clear. I believe that's the same way we took it too. A few investors came to us with questions regarding Russia and Ukraine, and whether we had any broad perspective on what's developing in that region and how it might truly affect your operations.

Brian Schopfer

executive
#31

Let me start with the numbers, and then Tom, feel free to jump in with more detail. When we look at what we've got going on in Russia and Ukraine, Russia is really the main piece for us. Roughly 10 million dollars of direct business goes into Russia. Beyond that, clearly we're working alongside partners on reactors backed by Russia, or using Russian technology, that are being constructed in places like Huntington and Finland. As we see it today, some cash could shift a bit to the right, yet we don't anticipate any P&L effect right now. That's basically the way we're approaching it internally, and we'll keep monitoring what is clearly a situation that keeps changing.

Joe Ritchie

executive
#32

Understood, excellent. One final item, since it also appeared in the documents you filed today. Regarding the COO leaving, could you provide any context? Had you always planned to do away with that role? Any perspective you can share on this would be useful.

Tom Logan

executive
#33

So yes, what we anticipated was that once the public exit was completed, we'd eventually see our operating model evolve again, with the main business units—or the two segment leaders—reporting straight to me. That's how it's worked for the bulk of our history, with operating unit heads reporting directly to me, and that was true even well before we intended the spec exit, as we were getting ready to leave the other company. Having a COO role was really valuable, since it let operations be managed more directly while I could put my limited bandwidth toward exit processes and other strategic matters. With that now finished, we have the freedom to go back to the historical structure, with more direct contact and interaction between the unit leaders and me. So as we considered how the operating model should evolve, this is something we'd been thinking about for a good while. As for the actual departure mentioned in the 8-K, that call was made a few days ago. It was definitely within the SEC filing window for the 8-K, and it's really separate from the more strategic structural changes to the operating model that I mentioned.

Joe Ritchie

executive
#34

That's clear. Tom, Larry, Brian, and Alex, thank you. I truly value all the time today.

Tom Logan

executive
#35

Thanks, Joe, and thanks as well, Ronny.

Tom Logan

executive
#36

Everyone, this marks the initial quarterly results webcast we've held for the public, and it's a pleasure to have all of you tuning in and taking part today. Once more, I'll wrap up by noting that our confidence in the company's current position is strong, and we likewise feel positive regarding the plan and the broader industry environment we anticipate going forward, and we're eager to share an update on how things are advancing when the next quarter arrives; however, until then, once again, we appreciate the time and focus you've given us, and we anticipate being in touch with all of you down the road.

Operator

operator
#37

Thank you. That wraps up today's call, everyone. At this point, feel free to hang up your phones. We appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.